Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo

K

Kocaeli University

Status and phase

Completed
Phase 4

Conditions

Peripheral Vertigo

Treatments

Drug: 2 g piracetam intravenous
Drug: Administration of 100 mg dimenhydrinate intravenous

Study type

Interventional

Funder types

Other

Identifiers

NCT01890538
KOU KAEK 2013/174

Details and patient eligibility

About

This study aims to investigate efficacy of two different intravenous drugs (dimenhydrinate and piracetam) in the symptomatic management of peripheral vertigo. The patients will be randomized in two groups according to symptomatic treatment modalities: Dimenhydrinate (100 mg) and piracetam (2 g) will be given in 100 cc normal saline in 30 minutes. Each patient will be asked if her/his vertigo symptoms resolved or not, according to a numeric rating scale (0=no vertigo, 10=worst possible vertigo). The patient will be rate the intensity of symptoms in the following times: Numeric rating scale (1 to 10): Admission Numeric rating scale (1 to 10): After the study drug (No ambulation)* Numeric rating scale (1 to 10): After the study drug (Ambulation)* Ambulation refers to head movements or walking in the room, if applicable.

Enrollment

94 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Presenting to emergency department with vertigo symptoms
  • Adult patients (over 18)
  • Agree to participate to study (understanding the study protocol and signing the informed consent form)

Exclusion criteria

  • Patients under 18 years
  • Patients diagnosed with ischemic/hemorrhagic stroke after neuroimaging
  • Patient diagnosed with transient ischemic attack
  • Pregnants
  • Patients taking any analgesics or antihistaminic drugs last 24 hours
  • Documented or declared allergy to dimenhydrinate, piracetam or benzodiazepines
  • Patients who do not agree to participate to the study

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

94 participants in 2 patient groups

Piracetam
Active Comparator group
Description:
2 g intravenous piracetam
Treatment:
Drug: 2 g piracetam intravenous
Dimenhydrinate
Active Comparator group
Description:
Dimenhydrinate 100 mg intravenous
Treatment:
Drug: Administration of 100 mg dimenhydrinate intravenous

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems